Site-specific glycan analysis of the SARS-CoV-2 spike

SARS-CoV-2 spike protein, elaborated Vaccine development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is focused on the trimeric spike protein that initiates infection. Each protomer in the trimeric spike has 22 glycosylation sites. How these sites are glycosylated may affect which cells the virus can infect and could shield some epitopes from antibody neutralization. Watanabe et al. expressed and purified recombinant glycosylated spike trimers, proteolysed them to yield glycopeptides containing a single glycan, and determined the composition of the glycan sites by mass spectrometry. The analysis provides a benchmark that can be used to measure antigen quality as vaccines and antibody tests are developed. Science this issue p. 330 A mass spectrometry analysis reveals the glycan composition at all glycosylation sites on the SARS-CoV-2 spike protein. The emergence of the betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), represents a considerable threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fusion. The SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.

[1]  F. Krammer,et al.  SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.

[2]  John R Yates,et al.  Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer , 2018, Nature Communications.

[3]  N. Packer,et al.  Emerging roles of protein mannosylation in inflammation and infection. , 2016, Molecular aspects of medicine.

[4]  Alexis Rohou,et al.  cisTEM: User-friendly software for single-particle image processing , 2017, bioRxiv.

[5]  John R Yates,et al.  Global site-specific N-glycosylation analysis of HIV envelope glycoprotein , 2017, Nature Communications.

[6]  R. Dwek,et al.  Exploiting the defensive sugars of HIV-1 for drug and vaccine design , 2007, Nature.

[7]  Bette Korber,et al.  Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.

[8]  A. Walls,et al.  Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.

[9]  B. Hogue,et al.  Coronavirus envelope (E) protein remains at the site of assembly , 2015, Virology.

[10]  Darrell J Irvine,et al.  Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers , 2019, Science.

[11]  D. Roote,et al.  Status Report , 2006, Journal of periodontology.

[12]  M. Renfrow,et al.  Glycosylation of viral surface proteins probed by mass spectrometry , 2019, Current Opinion in Virology.

[13]  John P. Moore,et al.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer , 2016, Journal of Virology.

[14]  M. Crispin,et al.  Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope , 2015, Journal of Virology.

[15]  William R. Schief,et al.  Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV , 2014, Science Translational Medicine.

[16]  Silke Stertz,et al.  The intracellular sites of early replication and budding of SARS-coronavirus , 2007, Virology.

[17]  R. Desrosiers,et al.  Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding , 2016, Scientific Reports.

[18]  Alexis Rohou,et al.  cisTEM: User-friendly software for single-particle image processing , 2018 .

[19]  Pauline M Rudd,et al.  Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein , 2010, Virology.

[20]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[21]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[22]  Young Do Kwon,et al.  Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G , 2016, Cell.

[23]  K. Khoo,et al.  Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans , 2020, Proceedings of the National Academy of Sciences.

[24]  Andrea Marzi,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[25]  Zachary T. Berndsen,et al.  Vulnerabilities in coronavirus glycan shields despite extensive glycosylation , 2020, Nature Communications.

[26]  D. Burton,et al.  Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization , 2018, Immunity.

[27]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[28]  I. Wilson,et al.  Exploitation of glycosylation in enveloped virus pathobiology , 2019, Biochimica et Biophysica Acta (BBA) - General Subjects.

[29]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[30]  Paul Emsley,et al.  Structural analysis of glycoproteins: building N-linked glycans with Coot , 2018, Acta crystallographica. Section D, Structural biology.

[31]  David J. Harvey,et al.  Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen , 2018, Cell reports.

[32]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[33]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[34]  Raymond A. Dwek,et al.  Emerging Principles for the Therapeutic Exploitation of Glycosylation , 2014, Science.

[35]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[36]  D. Veesler,et al.  Structural and functional analysis of a potent sarbecovirus neutralizing antibody , 2020 .

[37]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[38]  Thomas Strecker,et al.  Structure of the Lassa virus glycan shield provides a model for immunological resistance , 2018, Proceedings of the National Academy of Sciences.

[39]  Weston B Struwe,et al.  Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein , 2016, Cell reports.

[40]  Chih-Jen Wei,et al.  Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design , 2010, Science Translational Medicine.

[41]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.